Vivos Therapeutics, Inc.

VVOS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$5,399-$5,013-$3,864-$2,827
Dep. & Amort.$384$306$177$144
Deferred Tax$0$0$0$0
Stock-Based Comp.$55$242$317$57
Change in WC-$445$871-$426-$319
Other Non-Cash$1,244$100$0$5
Operating Cash Flow-$4,161-$3,494-$3,796-$2,940
Investing Activities
PP&E Inv.$893-$771-$122-$165
Net Acquisitions$5,135-$5,135$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$5,945$0$0$0
Investing Cash Flow$83-$5,906-$122-$165
Financing Activities
Debt Repay.$0$9,642$0$0
Stock Issued$957$1,818$0$3,500
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2,763$0$0-$446
Financing Cash Flow$2,763$11,460$0$3,054
Forex Effect$0$0$0$0
Net Chg. in Cash-$1,315$2,060-$3,918-$51
Supplemental Information
Beg. Cash$4,402$2,342$6,260$6,311
End Cash$3,087$4,402$2,342$6,260
Free Cash Flow-$3,268-$4,265-$3,796-$3,105
Vivos Therapeutics, Inc. (VVOS) Financial Statements & Key Stats | AlphaPilot